MX2020003431A - Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol- 2,5-diona. - Google Patents

Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol- 2,5-diona.

Info

Publication number
MX2020003431A
MX2020003431A MX2020003431A MX2020003431A MX2020003431A MX 2020003431 A MX2020003431 A MX 2020003431A MX 2020003431 A MX2020003431 A MX 2020003431A MX 2020003431 A MX2020003431 A MX 2020003431A MX 2020003431 A MX2020003431 A MX 2020003431A
Authority
MX
Mexico
Prior art keywords
oxolo
fluorobenzofuran
indol
dione
pyrrole
Prior art date
Application number
MX2020003431A
Other languages
English (en)
Inventor
Yamin Zhang
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of MX2020003431A publication Critical patent/MX2020003431A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente divulgación se refiere a formas sólidas de 3-(5-Fluorobenzofuran-3-il)-4-(5-metil-5H- [1,3]dioxolo[4,5-f]indo l-7-il)pirrol-2,5-diona, procesos para la preparación de la misma, composiciones farmacéuticas de la misma, y usos de la misma en el tratamiento de enfermedades.
MX2020003431A 2017-10-16 2018-10-16 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol- 2,5-diona. MX2020003431A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572603P 2017-10-16 2017-10-16
PCT/US2018/056083 WO2019079299A1 (en) 2017-10-16 2018-10-16 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H- [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Publications (1)

Publication Number Publication Date
MX2020003431A true MX2020003431A (es) 2020-07-29

Family

ID=64110166

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003431A MX2020003431A (es) 2017-10-16 2018-10-16 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol- 2,5-diona.

Country Status (11)

Country Link
US (2) US11407759B2 (es)
EP (1) EP3697794A1 (es)
JP (2) JP2020536944A (es)
KR (1) KR20200100615A (es)
CN (1) CN111315748B (es)
AU (1) AU2018352384B2 (es)
BR (1) BR112020007538A2 (es)
CA (1) CA3074037A1 (es)
IL (1) IL273920A (es)
MX (1) MX2020003431A (es)
WO (1) WO2019079299A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018352384B2 (en) * 2017-10-16 2023-12-21 Actuate Therapeutics Inc. Solid forms of 3-[5-Fluorobenzofuran-3-yl]-4-[5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl] pyrrole-2,5-dione
CA3100381A1 (en) * 2018-05-17 2019-11-21 Actuate Therapeutics, Inc. Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
JP7424639B2 (ja) 2017-08-11 2024-01-30 アクチュエイト セラピューティクス インク． ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態
AU2018352384B2 (en) * 2017-10-16 2023-12-21 Actuate Therapeutics Inc. Solid forms of 3-[5-Fluorobenzofuran-3-yl]-4-[5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl] pyrrole-2,5-dione

Also Published As

Publication number Publication date
BR112020007538A2 (pt) 2020-09-24
JP2020536944A (ja) 2020-12-17
JP2024001040A (ja) 2024-01-09
CA3074037A1 (en) 2019-04-25
CN111315748A (zh) 2020-06-19
US20200239489A1 (en) 2020-07-30
WO2019079299A1 (en) 2019-04-25
IL273920A (en) 2020-05-31
AU2018352384B2 (en) 2023-12-21
KR20200100615A (ko) 2020-08-26
CN111315748B (zh) 2023-06-27
AU2018352384A1 (en) 2020-05-21
EP3697794A1 (en) 2020-08-26
US20220348591A1 (en) 2022-11-03
US11407759B2 (en) 2022-08-09

Similar Documents

Publication Publication Date Title
CA211013S (en) Vaporizer device
MX2020004287A (es) Procesamiento de biomasa.
MA44890A (fr) Compositions comprenant des souches bactériennes
WO2018109174A3 (en) Il-11 antibodies
CR20200274A (es) Oxadiazoles fungicidas
AU2018258581A8 (en) RAF-degrading conjugate compounds
MX2019000985A (es) Recomendacion de accesorio.
MX2020003760A (es) Formulaciones de niraparib.
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
MX2020004071A (es) Derivados de aztreonam y usos de los mismos.
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
MX2020004424A (es) Formulacion aerosolizable.
MX2019009647A (es) Tapa para taza de pulpa moldeada.
IL272556A (en) Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H[3,1]dioxo[5,4-F]indol-7-yl)pyrrol-5,2-dione
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
MX2020004070A (es) Combinaciones de compuestos activos con propiedades insecticidas/acaricidas.
MX2020001844A (es) Metodos y sistema para aparatos dentales homogeneos.
MX2021012250A (es) Formas solidas de (e)-3-[2-(2-tienil)vinil]-1h-pirazol.
MX2022001764A (es) Composiciones que comprenden tigolaner para el control de parasitos.
MX2020003431A (es) Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol- 2,5-diona.
MX2017007955A (es) Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.
MX2020004245A (es) Estabilizador mejorado para poliamidas.
MX2020004288A (es) Catalizadores para elaborar materiales de oxazolidinona.
MX2020002908A (es) Composicion acuosa de polimeros.
WO2018211324A8 (en) Prodrugs for the treatment of disease